ADAGENE INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.54 USD | -3.79% |
|
-3.93% | +31.51% |
| Mar. 29 | Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 29 | Adagene Inc. Announces Board Changes | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 117M |
|---|---|---|---|---|---|
| Net income 2024 * | -49M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 91.82M | Net cash position 2025 * | 22.83M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3
x | P/E ratio 2025 * |
-1.62
x | Employees | 174 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.35% | ||
| 1 week | -6.38% | ||
| Current month | -5.71% | ||
| 1 month | -8.97% | ||
| 3 months | -21.66% | ||
| 6 months | +96.28% | ||
| Current year | +36.69% |
1 week
2.50
2.72
1 month
2.413.45
Current year
1.854.38
1 year
1.104.38
3 years
0.9020.98
5 years
0.9031.83
10 years
0.9031.83
| Managers | Title | Age | Since |
|---|---|---|---|
Peizhi Luo
CEO | Chief Executive Officer | 59 | 11-02-24 |
Man Kin Tam
DFI | Director of Finance/CFO | 47 | 19-08-31 |
JC Xu
CTO | Chief Tech/Sci/R&D Officer | 60 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peizhi Luo
CEO | Chief Executive Officer | 59 | 11-02-24 |
Mervyn Turner
BRD | Director/Board Member | 77 | 23-04-27 |
Cuong Viet Do
BRD | Director/Board Member | 58 | 22-11-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.54 | -3.79% | 5 227 |
| 24-04-18 | 2.64 | +4.35% | 1,778 |
| 24-04-17 | 2.53 | -6.30% | 11,375 |
| 24-04-16 | 2.7 | +3.85% | 5,813 |
| 24-04-15 | 2.6 | -1.66% | 8,465 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyâs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.64
USD
Average target price
5
USD
Spread / Average Target
+89.39%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +36.69% | 117M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.65% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ADAG Stock
